SOURCE: Sandoz

Sandoz

June 13, 2016 07:00 ET

Sandoz Canada Concludes a New Collective Agreement With Unionized Employees at Its Boucherville Plant

BOUCHERVILLE, QC--(Marketwired - June 13, 2016) - Sandoz Canada is pleased to announce that it has concluded a new, 6-year collective agreement with 267 unionized employees at its plant in Boucherville, Quebec who are members of the Teamsters, Local 1999. The last collective agreement expired on December 31, 2015. As a result of the agreement, the temporary allocation system put in place for injectable medicines manufactured at the plant will be lifted in the coming days.

"This new agreement is good news for all parties concerned, as well as for the Canadian healthcare system as we have one of the biggest injectables manufacturing plants in Canada, producing high quality lifesaving products," said Michel Robidoux, President and General Manager of Sandoz Canada. "Over the past 30 years, we have built a strong industrial peace with our employees and we are proud to see that it will continue for another 6-years," he added, noting that the company has more than 900 employees in Canada.

Mr. Robidoux noted that Sandoz Canada employees are critical in helping the company achieve its commitment of meeting patients' medical needs while maintaining the highest standards of quality, compliance and service, as well as supplying products at the best possible cost. "The plant environment in Boucherville is collaborative and our employees actively participate in continuous improvement initiatives. Sandoz is proud to be a good corporate citizen, providing competitive wages, interesting and important work, and the right environment to attract and retain the employees we need."

Over the past few years, Sandoz Canada has intensified its efforts to ensure high quality standards across its manufacturing operations. In order to implement Novartis Quality and Compliance world-class best practices, it has made significant investments to upgrade and modernize its Boucherville plant and to develop employees through training.

Sandoz Canada is part of Sandoz International GmbH and a subsidiary of Swiss multinational Novartis AG, the world's second largest producer of generic drugs. A leader in its field, Sandoz Canada develops, manufactures, markets and distributes a broad line of generic, biosimilar, consumer and specialty products.

About Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of over 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Contact Information